Scientific Presentation | AAIC 2023
Biomarker Analyses From the Phase 2, Randomized, Placebo-Controlled ACT-AD and Open-Label Extension Clinical Trials of Fosgonimeton in Patients With Mild-to-Moderate Alzheimer’s Disease
Hans J. Moebius, Kai-Bin C. Ooi, Michael D. Hale, Sharay E. Setti, Kayla N. Kleist, Josh Pan, Kevin J. Church, Marwan Sabbagh
Download PDF
Watch Video
You May Also Be Interested In...
AAN 2023
Moebius et al.
AAIC 2023
Reda et al.
AAN 2023
Reda et al.